H2O.ai Launches H2O AI Hybrid Cloud
26.1.2021 19:19:00 EET | Business Wire | Press release
H2O.ai announces H2O AI Hybrid Cloud, an end-to-end AI platform that enables organizations to build rapidly, share, and use AI models and applications.
An innovative new platform, H2O AI Hybrid Cloud, empowers anyone to innovate and use AI to make better forecasts, streamline operations, reduce risk, and personalize customer experiences. It contains capabilities and automation across the entire data science lifecycle, including connecting to and preparing data, building and explaining models, deploying and operating models, and building and sharing AI applications.
“AI is central to AT&T’s mission to deliver wireless, broadband, and software-based video to our customers. We’ve deployed hundreds of AI models to support those products and services, such as to protect our customers by scoring transactions in real-time for the likelihood of fraud. Collaborating with H2O around their open source tools including H2O Wave and H2O AI Hybrid Cloud will let us expand those capabilities across AT&T.” – Mark Austin, Vice President of Data Science, AT&T
H2O AI Hybrid Cloud is deployed on Kubernetes, enabling customers to operate on any cloud, such as Microsoft Azure or on-premises infrastructure.
The platform features over 200 data connectors, automatic data visualization, automatic feature engineering, AutoML for tabular, time-series, text, image, and video data, and machine learning operations technology to help organizations govern and continuously improve models. H2O AI Hybrid Cloud is integrated with Snowflake, enabling data engineers to make AI models and score records using their preferred language -- SQL.
"It used to take large teams of expert data scientists months, or longer, to develop a single model, but today, with Snowflake’s extensibility capabilities and H2O's AutoML technology, data engineers can rapidly build and deploy their models and score records, all from within Snowflake using SQL." - Snowflake Director of Product Management, Torsten Grabs
The H2O AI Hybrid Cloud integrates with the recently released H2O Wave and is built for organizations that want to put AI into their business users’ hands. An open-source lightweight Python development framework, this platform makes it easy for developers, data scientists, and machine learning engineers to make sophisticated applications that leverage AI models.
“The future is no-touch, seamless, frictionless automation, supported by deep insights. Powered by H2O AI Hybrid Cloud, Arogya Mitra Sejati is bringing to life Arogya, a deep insights based automated supply chain platform - optimized for healthcare.” - Vijay Sarashetti, Cofounder and CTO, Arogya
H2O AI Hybrid Cloud also provides an AppStore, enabling organizations to publish and share the AI applications they build with H2O Wave. The AppStore deploys with a set of pre-built applications, such as Automatic Insights, Recommendations, and LIBOR, which organizations can use to put AI into production even faster.
“AI is transforming the world. Organizations are adopting AI at increasing rates and need holistic, open and automated platforms to make world-class AI models and applications rapidly. H2O AI Hybrid Cloud enables organizations to make AI for virtually any use case, streamline machine learning operations and democratize AI across the organization.” -Sri Ambati, CEO, H2O.ai
To meet hybrid and multi-cloud requirements for enterprises, Red Hat OpenShift will certify the platform early this year.
“Red Hat OpenShift, the industry’s leading enterprise-grade, fully-supported Kubernetes platform, is optimized for H2O Driverless AI and H2O Open Source, making it easier for customers to deploy and manage H2O.ai products across the hybrid cloud. We are working closely with H2O.ai as they seek to certify H2O AI Hybrid Cloud on OpenShift in order to continue building on this momentum.” - Joe Fernandes, Vice President and General Manager, Cloud Platforms, Red Hat
About H2O.ai
H2O.ai is a leading AI technology company that enables organizations to rapidly build world-class AI models and applications. We continue to reimagine what is possible with artificial intelligence and deliver new platforms and technologies to put responsible AI into the hands of more users.
Our vision is to democratize AI by making it easier for individuals to build and access world-class and responsible AI. To achieve this vision, we’re creating a culture of responsible and engaged makers: community, customers, partners, entrepreneurs, and our own “makers,” and we’re enabling them with the technology to “make.” H2O is a leading open-source data science and machine learning platform used by nearly half of the Fortune 500 and trusted by over 20,000 organizations and hundreds of thousands of data scientists around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005850/en/
Contact information
Ana Visneski
anastacia.visneski@h2o.ai
206-498-1085
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
